Biotech firm PepGen's Q3 net loss narrows to $18 mln

Reuters11-12

Biotech firm PepGen's Q3 net loss narrows to $18 mln

Overview

PepGen Q3 net loss narrows to $18 mln from $21.4 mln in 2024
Company raised $115 mln, extending cash runway into 2H 2027
FREEDOM-DM1 study shows highest mean splicing correction in DM1 patients

Outlook

PepGen expects FREEDOM2 5 mg/kg cohort results in Q1 2026
Company plans to initiate 10 mg/kg dosing in FREEDOM2 in Q1 2026
PepGen's cash runway extended into second half of 2027

Result Drivers

Research and Development Expenses were $13.4 million for the three months ended September 30, 2025, compared to $17.7 million for the same period in 2024

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		-$0.52
Q3 Net Income		-$18.03 mln
Q3 Operating Expenses		$18.65 mln
Q3 Operating Income		-$18.65 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for PepGen Inc is $9.00, about 48.3% above its November 11 closing price of $4.65

Press Release: ID:nBwb11Pbha

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582756643?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582756643","market":"fut","top_or_hot":-1,"title":"Biotech firm PepGen's Q3 net loss narrows to $18 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biotech firm PepGen's Q3 net loss narrows to $18 mln</title></head><body><p><span>Overview</span></p><ul><li><p>PepGen Q3 net loss narrows to $18 mln from $21.4 mln in 2024</p></li><li><p>Company raised $115 mln, extending cash runway into 2H 2027</p></li><li><p>FREEDOM-DM1 study shows highest mean splicing correction in DM1 patients</p></li></ul><p><span>Outlook</span></p><ul><li><p>PepGen expects FREEDOM2 5 mg/kg cohort results in Q1 2026</p></li><li><p>Company plans to initiate 10 mg/kg dosing in FREEDOM2 in Q1 2026</p></li><li><p>PepGen's cash runway extended into second half of 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p><span>Research and Development Expenses</span> were $13.4 million for the three months ended September 30, 2025, compared to $17.7 million for the same period in 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.52</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$18.03 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$18.65 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$18.65 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", no \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for PepGen Inc is $9.00, about 48.3% above its November 11 closing price of $4.65</p></li></ul><p>Press Release: <span>ID:nBwb11Pbha</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech firm PepGen's Q3 net loss narrows to $18 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech firm PepGen's Q3 net loss narrows to $18 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 20:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biotech firm PepGen's Q3 net loss narrows to $18 mln</title></head><body><p><span>Overview</span></p><ul><li><p>PepGen Q3 net loss narrows to $18 mln from $21.4 mln in 2024</p></li><li><p>Company raised $115 mln, extending cash runway into 2H 2027</p></li><li><p>FREEDOM-DM1 study shows highest mean splicing correction in DM1 patients</p></li></ul><p><span>Outlook</span></p><ul><li><p>PepGen expects FREEDOM2 5 mg/kg cohort results in Q1 2026</p></li><li><p>Company plans to initiate 10 mg/kg dosing in FREEDOM2 in Q1 2026</p></li><li><p>PepGen's cash runway extended into second half of 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p><span>Research and Development Expenses</span> were $13.4 million for the three months ended September 30, 2025, compared to $17.7 million for the same period in 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.52</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$18.03 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$18.65 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$18.65 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", no \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for PepGen Inc is $9.00, about 48.3% above its November 11 closing price of $4.65</p></li></ul><p>Press Release: <span>ID:nBwb11Pbha</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PEPG","symbol_name":"PepGen Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0D4:1","article_id":"2582756643","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582756643","pubTimestamp":1762949461,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biotech firm PepGen's Q3 net loss narrows to $18 mlnOverviewPepGen Q3 net loss narrows to $18 mln from $21.4 mln in 2024Company raised $115 mln, extending cash runway into 2H 2027FREEDOM-DM1 study sho","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PEPG":"PepGen Inc.","BK4139":"生物科技"},"translate_title":"生物技术公司PepGen第三季度净亏损收窄至1800万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEPG":0.9},"content_text":"Biotech firm PepGen's Q3 net loss narrows to $18 mlnOverviewPepGen Q3 net loss narrows to $18 mln from $21.4 mln in 2024Company raised $115 mln, extending cash runway into 2H 2027FREEDOM-DM1 study shows highest mean splicing correction in DM1 patientsOutlookPepGen expects FREEDOM2 5 mg/kg cohort results in Q1 2026Company plans to initiate 10 mg/kg dosing in FREEDOM2 in Q1 2026PepGen's cash runway extended into second half of 2027Result DriversResearch and Development Expenses were $13.4 million for the three months ended September 30, 2025, compared to $17.7 million for the same period in 2024Key DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS-$0.52Q3 Net Income-$18.03 mlnQ3 Operating Expenses$18.65 mlnQ3 Operating Income-$18.65 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", no \"hold\" and 1 \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for PepGen Inc is $9.00, about 48.3% above its November 11 closing price of $4.65Press Release: ID:nBwb11PbhaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582756643","isCrawlerRequest":true}